Artificial intelligence is revolutionizing biopharma, but the real differentiator is how organizations turn vast datasets into decision-grade real-world evidence (RWE). In the latest Scrip Asks feature, Aetion’s CEO, Jeremy Rassen, discusses how industry leaders are leveraging AI, advanced analytics, and enterprise-grade technology to drive faster, more informed decision-making across clinical, regulatory, and commercial functions.